ClinicalTrials.gg
CompletedNCT06200597Updated Dec 17, 2025

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

A Phase 1 interventional study of LAD603 and Placebo in Healthy Volunteers, sponsored by Almirall, S.A.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Almirall, S.A. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple ascending doses of LAD603 in healthy adult participants in both Part 1 and 2.

Read the detailed description

This is a 2-part study. Part 1 will comprise up to 8 cohorts of healthy adult participants and investigate single ascending doses of LAD603. Part 2 will comprise up to 4 cohorts of healthy adult subjects and will investigate multiple ascending doses of LAD603. Each ascending dose level will be investigated by a sequential cohort, with dose escalation based on satisfactory safety, tolerability, PK, and pharmacodynamics (PD) (biomarker) data from the previous cohort(s). Dose levels evaluated in Part 2 of this study will not exceed dose levels that were safe and well tolerated in the single-dose study, and may be changed, depending on emerging safety and tolerability, PK, and PD (biomarker) data.

Each participant will participate for about 8 weeks in Part 1 and for about 14 weeks in Part 2 of the study.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Almirall, S.A. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is male or female aged between 18 and 65 years, inclusive, at the time of signing the .
  2. Participant is willing and able to understand and comply with study requirements
  3. Participant is willing to participate and have provided signed informed consent in accordance with institutional and regulatory guidelines, and authorization to use protected health information (Health Insurance Portability and Accountability Act [HIPAA]) prior to any study-related procedures being performed.
  4. Participant has a (BMI) of greater than or equal to (>=) 18.5 and less than or equal to (\<=) 29.9 kilogram per meter square (kg/m\^2) with a body weight of at least 60 kg.
  5. Participant is in good health as determined by medical history and has no abnormalities in the physical examination, vital signs, 12-lead , and laboratory tests as determined by the Investigator.
  6. Participant is a female who is not pregnant (i.e., does not have a positive serum pregnancy test on Day -1]) or breastfeeding, and who is either not a or is a WOCBP who agrees to follow the guidance for at least 28 days or 1 menstrual period (whichever is longer) prior to Day -1 until 30 days after the last dose of medical product (IMP) and to refrain from egg donation/collection until at least 60 days after the last dose of IMP OR Participant is a male who either had a vasectomy at least 90 days prior to Screening (with appropriate post vasectomy documentation of absence of sperm in the ejaculate) or who agrees to use contraception from the Day 1 visit until 30 days after the last dose of IMP and to refrain from sperm donation during this period, or is a vasectomized male who agrees to use a condom from the Day 1 visit until 30 days after the last dose of IMP.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, inflammatory, or allergic disease (including drug allergies, any active seizure disorder requiring therapy with antiepileptic drugs, active peptic ulcer disease, gastrointestinal bleeding, chronic gastritis, inflammatory bowel disease or chronic diarrhea, but excluding mild seasonal allergies or stable, well-controlled thyroiditis), a history of organ transplant, or is at increased risk for capillary leak syndrome.
  2. Participant has had major surgery (requiring general anesthesia) within 3 months prior to Baseline (Day -1).
  3. Participant has a history of cancer or lymphoproliferative disease within the previous 5 years, other than resected cutaneous basal cell, squamous cell carcinoma or carcinoma in situ of the cervix that has been treated with no evidence of recurrence.
  4. Participant has a clinically significant abnormality at Screening or Baseline (Day -1), including, but not limited to, the following:

    • An abnormal PR interval (>=220 millisecond [msec] or \<=100 msec)
    • prolongation (corrected QT interval by Fredericia's formula [QTcF] >=450 msec)
  5. Participant has a mean heart rate (HR) at Screening or Baseline (Day -1) that is \<=45 beats per minute (bpm) or >100 bpm
  6. Participant has systolic blood pressure \<90 millimeter of mercury (mmHg) or >140 mmHg or diastolic blood pressure \<50 mmHg or >90 mmHg at Screening or Baseline (Day -1)
  7. Participant with active chronic or acute infection including skin infection requiring treatment with systemic antimicrobials, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks before Baseline (Day -1), or skin infections within 4 weeks prior to Baseline (Day -1), or fever >38°C of unknown etiology within 1 week prior to Baseline (Day -1).
  8. Participant has known to any of the formulation of the IMP or previous severe adverse reaction to subcutaneous medication.
  9. Participant has hypersensitivity or reaction to a prior antibody-based biologic therapy (regardless of indication) that was clinically significant, as per judgment of Investigator.
  10. Participant has positive results for surface antigen (HBsAg), antihepatitis B core antigen (anti-HBcAg), antibody to the virus (anti-HCV), or antibody to the (HIV-1/2). A history of hepatitis B vaccination without history of hepatitis B is allowed.
  11. Participant has a positive test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) prior to dosing at Baseline (Day -1).
  12. Participant has received any type of live or attenuated vaccinations within 28 days prior to Baseline (Day -1), or is planning to receive any such vaccine during the study (inactive vaccines are allowed) or has received a SARS-CoV-2 vaccine within 14 days prior to Baseline (Day -1). Seasonal influenza and H1N1 vaccinations are permitted if the inactivated vaccine formulation is administered.
  13. Participant with history of active or latent tuberculosis, or recent close contact with an individual with active tuberculosis, or is positive at the Screening visit by tuberculin blood test (eg, QuantiFERON).
  14. Participant with congenital or acquired condition that would put participant at risk during the study.
  15. Participant with a history (within 6 months prior to Screening visit) of drug and/or alcohol abuse that may prevent trial compliance based on Investigator judgment.
  16. Females who are pregnant or breast-feeding or seeking to become pregnant during the study or for approximately 30 days after the last dose of IMP.
  17. Participant is a current smoker and is unable to restrain from smoking during the study.
  18. Participant has a positive test for drugs of abuse and/or alcohol.
  19. Participant has received any drug in any clinical study within 30 days (or at least 5 half-lives, whichever is longer) prior to Baseline (Day -1) or is on extended follow-up from such a clinical study
  20. Participant has taken any medications, including over-the-counter (OTC) medications, within 14 days (or at least 5 half-lives, whichever is longer) before Baseline (Day -1) (note that hormonal are allowed, and acetaminophen is permitted at doses \<=2 gram per day (g/day) up to 48 hours prior to each study visit), unless in the opinion of the Investigator and CRO Medical Monitor the medication will not interfere with the study procedures or compromise participant safety. Participants taking drugs that are substrates of cytochrome P450 or have a narrow therapeutic index are excluded from participating in this study.
  21. Participants with ANY of the following abnormalities in clinical laboratory tests at Screening or, if applicable, Day -1, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary:

    • Neutrophil or lymphocyte counts below the lower limit of the normal range.
    • Eosinophil count above the normal range (i.e., >500/mm\^3).
    • Estimated (GFR) by Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) calculation \<=90 mL/min/1.73 m\^2 at Screening.
    • (ALT), Aspartate aminotransferase (AST) or alkaline phosphatase (ALP) > (ULN).
    • Total >ULN
    • Other clinically significant abnormalities of laboratory assessments, as judged by the Investigator and/or Sponsor Medical Monitor that could affect the safety of the participant, or the interpretation of the data from the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Part 1: (LAD603) Cohort 1

    Participants will receive single ascending dose of LAD603 SC injection on Day 1.

    Drug: LAD603

  • Experimental
    Part 1: (LAD603) Cohort 2

    Participants will receive single ascending dose of LAD603 SC injection on Day 1.

    Drug: LAD603

  • Experimental
    Part 1: (LAD603) Cohort 3

    Participants will receive single ascending dose of LAD603 SC injection on Day 1.

    Drug: LAD603

  • Experimental
    Part 1: (LAD603) Cohort 4

    Participants will receive single ascending dose of LAD603 SC injection on Day 1.

    Drug: LAD603

  • Experimental
    Part 1: (LAD603) Cohort 5

    Participants will receive single ascending dose of LAD603 SC injection on Day 1.

    Drug: LAD603

  • Experimental
    Part 1: (LAD603) Cohort 6

    Participants will receive single ascending dose of LAD603 SC injection on Day 1.

    Drug: LAD603

  • Experimental
    Part 1: (LAD603) Cohort 7

    Participants will receive single ascending dose of LAD603 SC injection on Day 1.

    Drug: LAD603

  • Experimental
    Part 1: (LAD603) Cohort 8

    Participants will receive single ascending dose of LAD603 SC injection on Day 1.

    Drug: LAD603

  • Placebo comparator
    Part 1: Placebo

    Participants will receive single ascending dose of matching placebo SC injection on Day 1.

    Other: Placebo

  • Experimental
    Part 2: (LAD603) Cohort A

    Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.

    Drug: LAD603

  • Experimental
    Part 2: (LAD603) Cohort B

    Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.

    Drug: LAD603

  • Experimental
    Part 2: (LAD603) Cohort C

    Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.

    Drug: LAD603

  • Experimental
    Part 2: (LAD603) Cohort D

    Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.

    Drug: LAD603

  • Placebo comparator
    Part 2: Placebo

    Participants will receive multiple ascending dose of matching placebo SC injection on Days 1, 8 15, and 22.

    Other: Placebo

Interventions

  • DrugLAD603

    LAD603 SC injection.

  • OtherPlacebo

    Matching placebo SC injection.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants with Adverse Events (AEs) and Severity of AEs

    Time frame: Baseline up to Day 31

  2. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign Parameter

    Time frame: Baseline up to Day 31

  3. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Electrocardiograms (ECGs) Parameters

    Time frame: Baseline up to Day 31

  4. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters

    Time frame: Baseline up to Day 31

  5. Part 2: Number of Participants with AEs and Severity of AEs

    Time frame: Baseline up to Day 64

  6. Part 2: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign Parameter

    Time frame: Baseline up to Day 64

  7. Part 2: Number of Participants with Clinically Significant Changes from Baseline in ECGs Parameters

    Time frame: Baseline up to Day 64

  8. Part 2: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters

    Time frame: Baseline up to Day 64

Secondary outcomes

  1. Part 1: Maximum Serum Concentration (Cmax) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  2. Part 1: Minimum Serum Concentration (Cmin) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  3. Part 1: Time to Reach Maximum Serum Concentration (Tmax) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  4. Part 1: Area Under the Serum Concentration-time Curve (AUC) from Zero to Time of the Last Concentration (AUC0-t) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  5. Part 1: Area Under the Serum Concentration-time Curve (AUC) from Zero to infinity (AUC0-inf) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  6. Part 1: Area Under the Serum Concentration-time Curve (AUC) from Zero to 1 Week After Investigational Medicinal Product (IMP) Administration (AUC0-1w) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  7. Part 1: Elimination Half-life (t½) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  8. Part 1: Smallest Terminal Elimination Rate Constant (λz) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  9. Part 1: Apparent Total Serum Clearance (CL/F) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  10. Part 1: Mean Residence Time (MRT) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  11. Part 1: Apparent Volume of Distribution Associated with the Terminal Phase (Vz/F) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: at 24 and 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 120 hours (Day 6), 168 hours (Day 8), 240 hours (Day 11); 336 hours (Day 15), 504 hours (Day 22), 672 hours (Day 29)

  12. Part 2: Area Under the Concentration-time Curve within a Dosing Interval (AUCτ) of LAD603

    Time frame: Pre-dose, 2, 6, and 12 hours post-dose (Day 1)

  13. Part 2: Maximum Serum Concentration (Cmax) of LAD603

    Time frame: Pre-dose, 2, 6, and 12 hours post-dose (Day 1)

  14. Part 2: Time to Reach Maximum Serum Concentration (Tmax) of LAD603

    Time frame: Pre-dose, 2, 6, and 12 hours post-dose (Day 22)

  15. Part 2: Area Under the Concentration-time Curve within a Dosing Interval (AUCτ) at Steady State of LAD603

    Time frame: Pre-dose, 2, 6, and 12 hours post-dose (Day 22)

  16. Part 2: Average Steady State Serum Drug Concentration (Cav,ss)

    Time frame: Pre-dose, 2, 6, and 12 hours post-dose (Day 22)

  17. Part 2: Elimination Half-life (t½) of LAD603

    Time frame: Pre-dose, 2, 6, and 12 hours post-dose (Day 22)

  18. Part 2: Smallest Terminal Elimination Rate Constant (λz) of LAD603

    Time frame: Pre-dose, 2, 6, and 12 hours post-dose (Day 22)

  19. Part 2: Accumulation Ratios (RA) at Steady State Based on AUCτ (RA[AUC]) of LAD603

    Time frame: Pre-dose, 2, 6, and 12 hours post-dose (Day 22)

  20. Part 2: Accumulation Ratios (RA) at Steady State Based on Cmax (RA[Cmax]) of LAD603

    Time frame: Pre-dose, 2, 6, and 12 hours post-dose (Day 22)

  21. Part 2: Serum Concentration Observed at the Last Planned Sampling Timepoint Prior to Dosing (Ctrough; RA[Ctrough]) of LAD603

    Time frame: Pre-dose, 2, 6, and 12 hours post-dose (Day 22)

  22. Part 2: Serum Concentration Observed at the Last Planned Sampling Timepoint Prior to Dosing (Ctrough) of LAD603

    Time frame: Pre-dose, 2, 6, 12 hours (Day 1); Post-dose: 24 and 36 hours (Day 2), 48 hours (Day 3), 96 hours (Day 5), 168 hours (Day 8); Pre-dose (Day 15); Pre-dose, 2, 6, and 12 hours post-dose (Day 22)

07

Study locations

1 site
  • ICON Phase 1 unit Lenexa
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in May 2025, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2023
First posted
Jan 11, 2024
StartActual
Dec 5, 2023
Primary completionActual
May 11, 2025
CompletionActual
May 29, 2025
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06200597
Lead sponsor
Almirall, S.A.
Responsible party
Sponsor
First posted
Jan 11, 2024
Start date
Dec 5, 2023
Primary completion
May 11, 2025
Completion
May 29, 2025
Last update
Dec 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion